Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma
The clinical efficacy of neoadjuvant intratumoral TAVO-EP + nivolumab is promising with 80% of patients achieving an MPR. Evidence of potent immune activation both systemically and within the TME along with a favorable safety profile supports the activity of local IL-12 and anti-PD-1 based regimens.
Authors
- Deanryan B. De Aquino
- Jane L. Messina (ORCID: https://orcid.org/0000-0002-0332-0224)
- Edith Abraham
- Ahmad A. Tarhini (ORCID: https://orcid.org/0000-0002-3193-9702)
- Jonathan S. Zager (ORCID: https://orcid.org/0000-0002-6886-4468)
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Amod A. Sarnaik (ORCID: https://orcid.org/0000-0002-2337-5898)
- Michael J. Schell (ORCID: https://orcid.org/0000-0003-4594-6601)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Vernon K. Sondak (ORCID: https://orcid.org/0000-0003-1090-484X)
- Allison Richards (ORCID: https://orcid.org/0000-0003-3438-5589)
- David A. Canton (ORCID: https://orcid.org/0000-0003-2770-7607)
- Denise Kalos (ORCID: https://orcid.org/0009-0008-0576-3222)
- Diana Acevedo
- Islam Eljilany (ORCID: https://orcid.org/0000-0001-6387-5419)
- Pei-Ling Chen (ORCID: https://orcid.org/0000-0001-6025-4318)
- R. Gonzalez (ORCID: https://orcid.org/0000-0002-9701-9271)
- Carl Wayne Cruse (ORCID: https://orcid.org/0009-0006-2081-4388)
Institutions
- Moffitt Cancer Center (US)
- University of California San Diego Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2768
- Citations
- 9
- Primary Topic
- Microbial Inactivation Methods
- Type
- article
- Field-Weighted Citation Impact
- 3.48
Funders
- Pfizer
- Sanofi
- Moffitt Cancer Center
- Regeneron Pharmaceuticals
- OncoSec Medical
- Eisai
- InflaRx
- National Institutes of Health
- Genentech
- National Cancer Institute